Vaccination Against Covid in Primary Immune Deficiencies

Background and research question: Primary immune deficiencies (PIDs), also known as Inborn Errors of Immunity (IEI), are clinically characterized by an increased risk of severe infections. Therefore, these patients may also have an increased risk of adverse outcome of COVID-19 or may experience protracted course of disease. Effective SARS-CoV-2 vaccination would therefore be of great clinical importance in PIDs. However, until now not much is known about the efficacy and safety of SARS-CoV-2 vaccination in these vulnerable patients. In PID patients, the underlying disease may have a significant impact on the ability to develop an effective immune response after SARS-CoV-2 vaccination. Therefore this study aims to assess efficacy and safety of SARS-CoV-2 vaccination in patients with various forms of PID Hypothesis: PID patients show diminished B and T cell response after SARS-CoV-2 vaccination and these patients require intensified vaccination regimens